Yuhan Corp
KRX:000100
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
57 999.9966
163 700
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Yuhan Corp stock under the Base Case scenario is 54 100.21 KRW. Compared to the current market price of 115 100 KRW, Yuhan Corp is Overvalued by 53%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Yuhan Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Yuhan Corp cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Yuhan Corp., a leading player in South Korea's pharmaceutical industry, has a rich history dating back to its founding in 1926. The company has successfully built a strong reputation for innovation and reliability, developing a diverse portfolio that includes prescription drugs, over-the-counter medications, and biopharmaceuticals. Yuhan stands out not only for its robust domestic market presence but also for its strategic global partnerships, which have allowed it to expand its reach and enhance its product offerings. Investors can appreciate Yuhan's focus on research and development, as evidenced by its significant investment in cutting-edge therapies and advanced drug formulations that ca...
Yuhan Corp., a leading player in South Korea's pharmaceutical industry, has a rich history dating back to its founding in 1926. The company has successfully built a strong reputation for innovation and reliability, developing a diverse portfolio that includes prescription drugs, over-the-counter medications, and biopharmaceuticals. Yuhan stands out not only for its robust domestic market presence but also for its strategic global partnerships, which have allowed it to expand its reach and enhance its product offerings. Investors can appreciate Yuhan's focus on research and development, as evidenced by its significant investment in cutting-edge therapies and advanced drug formulations that cater to unmet medical needs.
In recent years, Yuhan Corp. has intensified its commitment to growth through collaborations with international companies, enhancing its capabilities in areas such as oncology, autoimmune disorders, and neurology. These partnerships position Yuhan well to capitalize on global market trends and shifting healthcare demands, offering promising avenues for revenue generation. As an investor, one would find comfort in Yuhan's strong financial performance, characterized by steady revenue growth, increasing profitability, and prudent cost management. With a forward-looking vision and a solid foundation, Yuhan Corp. represents a compelling opportunity for those interested in tapping into the thriving pharmaceutical sector and benefiting from innovations that improve healthcare outcomes globally.
Yuhan Corporation, based in South Korea, is a leading pharmaceutical and biotechnology company. Its core business segments primarily encompass:
-
Pharmaceuticals: This is the largest segment of Yuhan Corp. and includes the development and sale of prescription drugs. The company focuses on innovative medicines, particularly in fields like oncology, cardiology, and central nervous system disorders. Yuhan has a robust pipeline of new drug candidates and engages in research and development to expand its portfolio.
-
Consumer Health Products: Yuhan manufactures and markets over-the-counter (OTC) products, dietary supplements, and personal care items. This segment contributes to the company's revenues through a range of health and wellness products aimed at consumers.
-
Biotechnology: This segment is dedicated to the research and development of biopharmaceuticals, including biologics and biosimilars. Yuhan is actively involved in collaborations and partnerships to advance its biotechnological initiatives.
-
Contract Manufacturing and Research Services: Yuhan offers contract manufacturing services for other pharmaceutical companies. This segment allows Yuhan to leverage its expertise in manufacturing and supply chain management while providing services to clients.
-
International Sales and Collaborations: Yuhan is also focused on expanding its international footprint through partnerships and collaborations with global pharmaceutical companies. This segment involves licensing agreements, joint ventures, and co-development projects aimed at bringing innovative products to market worldwide.
Each of these segments demonstrates Yuhan Corp's commitment to innovation, quality, and addressing global healthcare needs, aligning with the principles of value investing that emphasize strong fundamentals and growth potential.
Yuhan Corporation, a South Korean pharmaceutical company, has several competitive advantages that set it apart from its rivals:
-
Strong R&D Capabilities: Yuhan Corp invests significantly in research and development, leading to a robust pipeline of novel drugs. This focus on innovation enables the company to stay ahead in the competitive pharmaceutical landscape.
-
Established Relationships and Partnerships: Yuhan has formed strategic partnerships with global pharmaceutical companies. These collaborations facilitate knowledge transfer, access to advanced technologies, and greater market reach.
-
Diversified Product Portfolio: The company offers a wide range of products, including prescription drugs, over-the-counter medicines, and biosimilars. This diversification helps mitigate risks associated with reliance on a single product.
-
Regulatory Expertise: Yuhan has a deep understanding of the regulatory environments in various markets, which allows for efficient navigation of compliance and faster time-to-market for new products.
-
Strong Market Position in Korea: Being one of the leading pharmaceutical companies in South Korea, Yuhan benefits from brand recognition and customer loyalty within its domestic market.
-
Focus on Specialty Drugs: Yuhan has a strategic focus on specialty pharmaceuticals, particularly in areas like oncology and cardiology, which often have less competition and higher profit margins.
-
Quality Manufacturing Standards: The company adheres to high manufacturing and quality standards, which enhances its reputation and credibility among healthcare professionals and consumers.
-
Effective Sales and Distribution Network: Yuhan has developed a strong sales and distribution network, ensuring effective market penetration and product availability, which is crucial for maintaining a competitive edge.
By leveraging these advantages, Yuhan Corporation can effectively compete in the dynamic pharmaceutical market, ensuring sustainable growth and profitability.
Yuhan Corp., a leading South Korean pharmaceutical and biotechnology company, may face several risks and challenges in the near future:
-
Regulatory Changes: The pharmaceutical industry is highly regulated. Changes in regulations, approval processes, or reimbursement policies in Korea or other global markets can impact Yuhan Corp’s operations and profitability.
-
Competition: The company faces competition from both local and international pharmaceutical firms. With the rising number of biotech companies, innovative treatments, and generics, maintaining market share can be challenging.
-
R&D Challenges: Developing new drugs is a lengthy and costly process. Yuhan Corp may encounter difficulties in research and development, including high failure rates in clinical trials, which can lead to financial losses.
-
Market Dynamics: Shifts in market demand due to economic downturns, changes in healthcare policies, or public perception of pharmaceuticals can affect sales.
-
Supply Chain Disruptions: Global supply chain issues, which can be amplified by geopolitical tensions, pandemics, or natural disasters, could hinder the production and distribution of Yuhan Corp’s products.
-
Intellectual Property Issues: Patent expirations or challenges against its patents might lead to increased competition from generic drugs, affecting revenue from key products.
-
Financial Risks: Currency fluctuations, especially if Yuhan Corp sources materials or sells products internationally, can impact financial stability.
-
Talent Acquisition and Retention: The ability to attract and retain skilled personnel in a competitive industry is crucial for ongoing innovation and growth.
-
Public Relations and Ethical Issues: Any negative publicity regarding drug pricing, safety concerns, or unethical practices can impact reputation and sales.
-
Global Expansion Risks: If Yuhan Corp aims to expand into new markets, it might face cultural, legal, and operational challenges that could hinder successful entry.
Addressing these risks requires a well-crafted strategy, including diversification, investment in R&D, robust risk management practices, and a strong focus on compliance and ethics.
Revenue & Expenses Breakdown
Yuhan Corp
Balance Sheet Decomposition
Yuhan Corp
Current Assets | 1.3T |
Cash & Short-Term Investments | 248.8B |
Receivables | 694.6B |
Other Current Assets | 366.1B |
Non-Current Assets | 1.6T |
Long-Term Investments | 626.5B |
PP&E | 586.7B |
Intangibles | 293.8B |
Other Non-Current Assets | 109.2B |
Current Liabilities | 570.5B |
Accounts Payable | 160.5B |
Accrued Liabilities | 37.5B |
Short-Term Debt | 131.7B |
Other Current Liabilities | 240.8B |
Non-Current Liabilities | 237.2B |
Long-Term Debt | 127.2B |
Other Non-Current Liabilities | 110B |
Earnings Waterfall
Yuhan Corp
Revenue
|
2T
KRW
|
Cost of Revenue
|
-1.3T
KRW
|
Gross Profit
|
675.7B
KRW
|
Operating Expenses
|
-603B
KRW
|
Operating Income
|
72.6B
KRW
|
Other Expenses
|
92.6B
KRW
|
Net Income
|
165.3B
KRW
|
Free Cash Flow Analysis
Yuhan Corp
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Yuhan Corp's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Yuhan Corp's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Yuhan Corp's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Yuhan Corp's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Yuhan Corp
According to Wall Street analysts, the average 1-year price target for Yuhan Corp is 108 256 KRW with a low forecast of 75 750 KRW and a high forecast of 163 800 KRW.
Dividends
Current shareholder yield for Yuhan Corp is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Yuhan Corp. engages in the manufacture of pharmaceutical, health foods, cosmetics and consumer products. The company is headquartered in Seoul, Seoul. The firm operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The firm also sells licenses. The firm distributes its products in domestic and overseas markets such as Europe, Asia and United States.
Contact
IPO
Employees
Officers
The intrinsic value of one Yuhan Corp stock under the Base Case scenario is 54 100.21 KRW.
Compared to the current market price of 115 100 KRW, Yuhan Corp is Overvalued by 53%.